Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

929 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C.
Nelson DR, Rustgi V, Balan V, Sulkowski MS, Davis GL, Muir AJ, Lambiase LR, Dickson RC, Weisner RH, Fiscella M, Cronin PW, Pulkstenis E, McHutchison JG, Subramanian GM. Nelson DR, et al. Clin Gastroenterol Hepatol. 2009 Feb;7(2):212-8. doi: 10.1016/j.cgh.2008.10.035. Epub 2008 Nov 7. Clin Gastroenterol Hepatol. 2009. PMID: 19061971 Clinical Trial.
Direct-acting antiviral agents and the path to interferon independence.
Schmidt WN, Nelson DR, Pawlotsky JM, Sherman KE, Thomas DL, Chung RT. Schmidt WN, et al. Among authors: nelson dr. Clin Gastroenterol Hepatol. 2014 May;12(5):728-37. doi: 10.1016/j.cgh.2013.06.024. Epub 2013 Jul 18. Clin Gastroenterol Hepatol. 2014. PMID: 23872239 Free PMC article. Review.
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.
Gordon SC, Muir AJ, Lim JK, Pearlman B, Argo CK, Ramani A, Maliakkal B, Alam I, Stewart TG, Vainorius M, Peter J, Nelson DR, Fried MW, Reddy KR; HCV-TARGET study group. Gordon SC, et al. Among authors: nelson dr. J Hepatol. 2015 Feb;62(2):286-93. doi: 10.1016/j.jhep.2014.08.052. Epub 2014 Sep 10. J Hepatol. 2015. PMID: 25218788 Free PMC article. Clinical Trial.
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA; ALLY-3 Study Team. Nelson DR, et al. Hepatology. 2015 Apr;61(4):1127-35. doi: 10.1002/hep.27726. Epub 2015 Mar 10. Hepatology. 2015. PMID: 25614962 Free PMC article. Clinical Trial.
Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.
Saxena V, Khungar V, Verna EC, Levitsky J, Brown RS Jr, Hassan MA, Sulkowski MS, O'Leary JG, Koraishy F, Galati JS, Kuo AA, Vainorius M, Akushevich L, Nelson DR, Fried MW, Terrault N, Reddy KR. Saxena V, et al. Among authors: nelson dr. Hepatology. 2017 Oct;66(4):1090-1101. doi: 10.1002/hep.29258. Epub 2017 Sep 4. Hepatology. 2017. PMID: 28504842 Free PMC article.
929 results